Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of DMB-3111 and Herceptin in Healthy Japanese Male Adults
jRCT2080222436Phase 1
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DMB-3111 in breast cancer and Gastric cancer (HER2-positive) (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints.
02
Drugs
DMB-3111
03
Conditions
breast cancerGastric cancer (HER2-positive)
Beyond the preview
Go deeper on jRCT2080222436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222436.